Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 148

Results For "IDA"

1801 News Found

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed
interviews | February 09, 2022

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India

C2i Genomics Partners with Twist Bioscience for cancer detection
Biotech | February 09, 2022

C2i Genomics Partners with Twist Bioscience for cancer detection

Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe

Glenmark launches nasal spray to treat Covid-19
News | February 09, 2022

Glenmark launches nasal spray to treat Covid-19

Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process

Piramal Pharma Solutions plans expansion in Scotland
News | February 09, 2022

Piramal Pharma Solutions plans expansion in Scotland

In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three

Granules India Q3FY22 PAT at Rs 100.88 cr.
News | February 08, 2022

Granules India Q3FY22 PAT at Rs 100.88 cr.

Granules India has reported consolidated financial results for the period ended December 31, 2021

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
News | February 08, 2022

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.

Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021

Suven Pharma Q3FY22 PAT at Rs. 160.06 crore
News | February 08, 2022

Suven Pharma Q3FY22 PAT at Rs. 160.06 crore

Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.

Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
Biotech | February 08, 2022

Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis

Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane

Merck KGaA restructures life science business to support long-term growth
News | February 08, 2022

Merck KGaA restructures life science business to support long-term growth

Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore
News | February 05, 2022

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore

Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021

Latest Stories

Dr. Jitendra Singh inaugurates animal stem cell BioBank and laboratory at NIAB, Hyderabad

Lupin launches Glucagon for Injection USP, 1mg/Vial in US

Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging